Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (931-940 of 1,052) with videos related to

Pageof 106
Sort By:
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T CellsCheng-Fu Kuo, Zhen Tong, Yi-Chiu Kuo, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Blood|September 4, 2020
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALLYaqi Zhao, Ibrahim Aldoss, Chunxu Qu, et al.
Blood|November 14, 1997
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk groupA Nademanee, A Molina, M R O'Donnell, et al.
Blood|June 10, 2011
Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)Saro H Armenian, Can-Lan Sun, Toana Kawashima, et al.
Cell Reports. Medicine|August 16, 2025
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safetyMichael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remissionAnthony S Stein, Margaret R O'Donnell, Marilyn L Slovak, et al.
Oncoimmunology|January 9, 2018
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancerSaul J Priceman, Ethan A Gerdts, Dileshni Tilakawardane, et al.
Pageof 106

Showing results (931-940 of 1,052) with videos related to

Sort By:
Pageof 106
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T CellsCheng-Fu Kuo, Zhen Tong, Yi-Chiu Kuo, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Blood|September 4, 2020
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALLYaqi Zhao, Ibrahim Aldoss, Chunxu Qu, et al.
Blood|November 14, 1997
Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk groupA Nademanee, A Molina, M R O'Donnell, et al.
Blood|June 10, 2011
Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)Saro H Armenian, Can-Lan Sun, Toana Kawashima, et al.
Cell Reports. Medicine|August 16, 2025
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safetyMichael E Barish, Maryam Aftabizadeh, Jonathan Hibbard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remissionAnthony S Stein, Margaret R O'Donnell, Marilyn L Slovak, et al.
Oncoimmunology|January 9, 2018
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancerSaul J Priceman, Ethan A Gerdts, Dileshni Tilakawardane, et al.
Pageof 106